Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Opioid prescribing patterns for non-malignant chronic pain for rural versus non-rural US adults: a population-based study using 2010 NAMCS data

  • Jacob P Prunuske1,
  • Catherine A St. Hill2,
  • Keri D Hager3,
  • Andrine M Lemieux4,
  • Michael T Swanoski3,
  • Grant W Anderson3 and
  • M Nawal Lutfiyya3, 5Email author
BMC Health Services Research201414:563

https://doi.org/10.1186/s12913-014-0563-8

Received: 31 January 2014

Accepted: 24 October 2014

Published: 19 November 2014

Abstract

Background

Non-malignant chronic pain (NMCP) is one of the most common reasons for primary care visits. Pain management health care disparities have been documented in relation to patient gender, race, and socioeconomic status. Although not studied in relation to chronic pain management, studies have found that living in a rural community in the US is associated with health care disparities. Rurality as a social determinant of health may influence opioid prescribing. We examined rural and non-rural differences in opioid prescribing patterns for NMCP management, hypothesizing that distinct from education, income, racial or gender differences, rural residency is a significant and independent factor in opioid prescribing patterns.

Methods

2010 National Ambulatory Medical Care Survey (NAMCS) data were examined using bivariate and multivariate techniques. NAMCS data were collected using a multi-stage sampling strategy. For the multivariate analysis performed the SPSS complex samples algorithm for logistic regression was used.

Results

In 2010 an estimated 9,325,603 US adults (weighted from a sample of 2745) seen in primary care clinics had a diagnosis of NMCP; 36.4% were prescribed an opioid. For US adults with a NMCP diagnosis bivariate analysis revealed rural residents had higher odds of having an opioid prescription than similar non-rural adults (OR = 1.515, 95% CI 1.513-1.518). Complex samples logistic regression analysis confirmed the importance of rurality and yielded that US adults with NMCP who were prescribed an opioid had higher odds of: being non-Caucasian (AOR =2.459, 95% CI 1.194-5.066), and living in a rural area (AOR =2.935, 95% CI 1.416-6.083).

Conclusions

Our results clearly indicated that rurality is an important factor in opioid prescribing patterns that cannot be ignored and bears further investigation. Further research on the growing concern about the over-prescribing of opioids in the US should now include rurality as a variable in data generation and analysis. Future research should also attempt to document the ecological, sociological and political factors impacting opioid prescribing and care in rural communities. Prescribers and health care policy makers need to critically evaluate the implications of our findings and their relationship to patient needs, best practices in a rural setting, and the overall consequences of increased opioid prescribing on rural communities.

Keywords

NAMCS data Rural health Health care disparities Opioids Non-malignant chronic pain NMCP

Background

Chronic pain, commonly defined as the experience of episodic or continuous debilitating pain over time (weeks to months or longer), is a significant problem in the United States [1]-[4]. It is a phenomenon with a complex etiology manifest with both physical and psychological components [4]-[6]. At present nearly 1 in 3 or 100 million adults in the US suffer from chronic pain [4],[6]. Chronic pain in the US is estimated to cost approximately $560-$635 billion annually, an amount equal to about $2,000 per capita [6]. This cost estimate includes both direct and indirect costs that are approximately equal to one another.

Chronic pain adversely impacts communities, families, and individuals by significantly contributing to poor mental and physical health resulting in lost work productivity and disability [4]-[7]. In the US, non-malignant chronic pain (NMCP) is one of the most common reasons for primary care visits [1],[3],[8],[9]. At times when patients visit a healthcare professional for NMCP, inadequate training and resources may prevent proper assessment and management [7],[10],[11]. Pain management healthcare disparities have been documented in relation to patient gender [12],[13], race [3],[11],[14]-[16], and socioeconomic status [12],[17]. Although not studied in relation to chronic pain management, studies have found that living in a rural community in the US is associated with healthcare disparities [18].

Opioids are commonly used in chronic pain management. Opioids are being overprescribed with possible negative consequences for individuals, families and communities. These consequences include: unintended death [7], overdose [7], diversion [7], and crime [7]. There is an upward trend for overprescribing opioids. Rurality as a social determinant of health may influence opioid prescribing [18]. Some research has been conducted on different types of chronic pain and opioid prescribing patterns including a geographic variable in the analysis. However, none of these studies undertook the task of answering a question about opioid prescribing and NMCP in rural versus non-rural adults using patient level health records [19]-[22]. This has created an epidemiological gap in our knowledge regarding opioid prescribing patterns for rural adults with NMCP.

Rasu, et al. [4] studied chronic pain management (medication and non-medication) in US ambulatory care settings. While they described the characteristics of their patient population, they did not examine the associations between patient characteristics and variations in prescribing patterns. They concluded that additional research should investigate patterns of NMCP management in various populations. Others [23],[24] have done this, but with older data. One study included geographic location of physician practice site in their analyses using rural locale as the reference category in multivariate analyses and found no significant relationship to opioid prescribing [25]. In this paper we hypothesize that distinct from patient race, education, income or gender, rural residency is a significant and an independent risk factor for the greater probability of receiving an opioid prescription for NMCP.

Methods

To answer the research question, 2010 National Ambulatory Medical Care Survey (NAMCS) data were examined using bivariate and multivariate techniques. NAMCS is designed to collect data on the utilization and provision of ambulatory care services nationwide. Data are collected from a national sample of ambulatory care visits. The survey employs a complex four-stage probability sampling design. A description of the sampling strategy is discussed elsewhere [25]. The 2010 NAMCS data were used for this study because they were the most recently available data. These data are weighted to be nationally representative of patient health records.

All analyses were performed on weighted data as is recommended by the Center for Disease Control and Prevention’s (CDC) National Center for Health Statistics (NCHS). The weighting, as calculated, uses the most recently available census data to provide a stratified representation of the nation’s patient population. Results report weighted data.

The survey uses a Patient Record Form as the survey instrument. The NAMCS patient record form is completed by ambulatory care staff for a systematic random sample of patient visits during a randomly assigned 1-week reporting period. Data are obtained on demographic characteristics of patients, expected source(s) of payment, patients’ complaints, diagnoses, diagnostic/screening services, procedures, medication therapy, disposition, types of providers seen, causes of injury, and certain characteristics of the facility, such as geographic region and metropolitan status.

Rurality, one of the key independent variables in this analysis, was derived using Metropolitan and Micropolitan Statistical Area (MSA) methodology. This is a definition used by federal level agencies for research purposes. MSA was recoded into the dichotomous categories of rural or non-rural. Rural residents were defined as people living either within an MSA that had no center city or outside an MSA. Non-rural residents included all respondents living in a center city of an MSA, outside the center city of an MSA but inside the county containing the center city, or inside a suburban county of an MSA.

The study population for this research was US adults with NMCP. NMCP is defined as pain lasting 3 months or more or as pain persisting beyond the time of expected healing. The three-digit ICD-9 code for NMCP is 338.2. The covariates or independent variables for this research were: geographic locale (rural/non-rural), patient sex (male/female), race/ethnicity (Caucasian/Non-Caucasian), age ranges (18-39/40-64/65 years and older), education attainment in a patient’s zip code (≤20% of adults with a university degree/> 20% of adults with a university degree), poverty level in patient’s zip code (<10%/≥ 10%) health insurance status (insured/noninsured), primary health care provider (HCP) seen (yes/no), depression diagnosis (yes/no), arthritis diagnosis (yes/no). Depression and arthritis diagnoses were included as variables because these may influence opioid prescribing [26],[27]. All of the study covariates were recoded from their original configuration for analyses. Re-coding entailed either collapsing categories and/or removing unknown responses. Opioid prescription was the dependent variable for this study.

The study variable that entailed complicated re-coding was the dependent variable-opioid prescription. Using the CDC’s New Ambulatory Care Drug Database System for NAMCS Data, prescribed drugs were classified as opioid or other. Table 1 displays the opioid drug codes by generic drug name.
Table 1

Opioid drug codes by generic drug name

Opioid drug codes from NAMCS drug database

Generic drug name

25510, 5660, 8335

Propoxyphene

2387, 97062

Remifentanil

1187, 50040

Sufentanil

9286

Tapentadol

2333, 5081, 5091, 8246, 9582, 22303, 91047, 96109, 97181

Oxycodone

7117, 7223, 21575

Oxymorphone

23285, 30535, 30540

Pentazocine

8338

Phenerol

7420, 8475, 8490, 10115

Propoxyphene

91046, 92044, 92070, 98144, 99123

Morphine

21550, 60990

Nalbuphine

8606, 98067

Narcotic Analgesics

3064, 9969, 21860, 21870, 21875, 21880, 22720, 22845

Opium

22850

Opium-Sodium Bicarbonate

1288, 1314

Oxycodone

95085

Hydroxyzine-Meperidine

17340, 17362

Levorphanol

200, 8785, 18760, 96045

Meperidine

10130, 18985

Methadone

85, 2852, 3228, 8079, 10743, 19650, 19699, 26763, 41420, 60940, 70214

Morphine

91071

Dezocine

9574

Dihydrocodeine

2067, 3307, 7197, 9508, 29645, 60565, 92024, 94188

Fentanyl

14770, 92041, 92042

Homatropine Methyl Bromide-Hydrocodone

7582, 9435, 14955, 94184

Hydrocodone

9600, 9641, 15005

Hydromorphone

11225, 22415, 27315

Aspirin; Caffeine; Codeine; Phenacetin

11090, 18425, 24770, 25525

Aspirin; Caffeine; Phenacetin; Propoxyphene

8910

Atropine; Opium; Phenacetin; Salicylamide

5054, 60265, 95036

Buprenorphine

5103

Butalbital-Codeine

1021, 29285

Butorphanol

1028, 7180, 7185 7190

Codeine

25690

Codeine; Sanguinaria; Terpin Hydrate; White Pine Syrup; Wild Cherry Syrup

91012

Dezocine

10715

Acetaminophen; Aspirin; Caffeine; Dihydrocodeine

42245

Acetaminophen; Aspirin; Caffeine; Hydrocodone

40765

Acetaminophen; Butabarbital; Codeine

13152, 24143

Acetaminophen; Butalbital; Codeine

866, 96145

Alfentanil

21095

Alphaprodine

2730, 2735

Aluminum Hydroxide; Aspirin; Codeine; Magnesium Antacids

2740

Aluminum Hydroxide; Aspirin; Codeine; Magnesium Hydroxide

12560

Aspirin; Butalbital; Caffeine; Codeine; Phenacetin

45, 50, 55, 65, 1990, 2815, 2825, 11220

Aspirin; Caffeine; Codeine; Phenacetin

3520

Acetaminophen; Codeine; Salicylamide

6284

Acetaminophen; Ethanol; Glycerin; Hydrocodone; Parabens

250, 265, 270, 275, 280, 1758, 2340, 2345, 5151, 5640, 7080, 7165, 7618, 9538, 11265, 11268, 23665, 23670, 23675, 23680, 25635, 28215, 32910, 32915, 32920, 32925, 32930, 32935, 41245, 91010

Acetaminophen-Codeine

197

Acetaminophen-Dextropropoxyphene

10128, 40415

Acetaminophen-Dihydrocodeine

251, 1268, 1995, 2045, 2082, 2132, 2314, 3518, 6059, 7064, 8354, 10105, 14917, 34110, 40860, 60340, 61610, 89038, 89039, 92180, 93077, 93089, 96028, 96047, 98036, 98168

Acetaminophen-Hydrocodone

8790

Acetaminophen-Meperidine

283, 2348, 3394, 7251, 7252, 7632, 8248, 22305, 22306, 23385, 26958, 28272, 32945, 91048, 99114

Acetaminophen-Oxycodone

7701, 30513

Acetaminophen-Pentazocine

156, 6232, 8470, 25530, 25545, 28340, 34985, 61240, 89071, 89072, 93053, 93411

Acetaminophen-Propoxyphene

11689, 95178

Apap; Butalbital; Caffeine; Codeine

44, 3078, 7467, 93351

Apap; Caffeine; Dihydrocodeine

12555, 12565, 12570, 15983, 40020

Asa; Butalbital; Caffeine; Codeine

30340

Asa; Caffeine; Dihydrocodeine

4215, 8480, 10120, 25505, 25515, 25520, 28345, 41375

Asa; Caffeine; Propoxyphene

5018

Aspirin; Buffers; Codeine

10285

Aspirin; Caffeine; Dover’s Powder

105, 2803, 2820, 11230, 11235, 11240, 11245, 11250, 11255, 11260

Aspirin-Codeine

8397, 92181, 93027

Aspirin-Hydrocodone

1099, 2828, 22307, 22308, 23390, 23395, 58273, 93250

Aspirin-Oxycodone

30530

Aspirin-Pentazocine

8485, 8495

Aspirin-Propoxyphene

2943, 2955

Atropine-Meperidine

19655

Atropine-Morphine

3245, 21865

Belladonna-Opium

9516

Bupivacaine-Hydromorphone

3276

Buprenorphine-Naloxone

15650, 89034

Droperidol-Fentanyl

9737, 9751, 98043

Hydrocodone-Ibuprofen

5040

Ibuprofen-Oxycodone

1098, 4534, 8093, 18755, 96012

Meperidine-Promethazine

4538

Naloxone-Pentazocine

Statistical Package for Social Scientists (SPSS, IBM, Chicago, IL, version 21.0) was used to complete all statistical analyses and alpha was set at p < 0.05. Bivariate contingency table analysis was conducted to establish the relationships between each of the covariates and the dependent variable. Bivariate analysis tests for a statistically significant relationship between an outcome or dependent variable and a predictor or independent variable. Bivariate analysis is not a stratified analysis. SPSS allows an unadjusted odds ratio to be computed from the contingency table analysis as long as the contingency table is a 2 × 2 table. If not, then a chi square may be computed as the test statistic for differences between percentages (e.g., 3-group age ranges and opioid prescription). Logistic regression analysis, to produce adjusted measures, was performed using SPSS (version 21.0) complex samples. The complex samples algorithm was used to account for the stratified, clustered, and weighted variables in the 2010 NAMCS survey data. This was essential since NAMCS data are collected using a survey design where a nationally representative sample of physicians and practice sites are examined and sample weights applied to obtain national population-based statistics. Detailed documentation of the NAMCS instrument, methodology, and data files that served as the basis for this study is available elsewhere [25]. The multivariate logistic regression model was performed using opioid prescription as the dependent variable, and adjusted odds ratios were produced to test significance and establish effects sizes. US adults with a diagnosis of NMCP was the population examined. For analysis the sample of 2,745 was weighted to represent 9,325,603 US adults with a diagnosis of NMCP.

The Institutional Review Boards (IRBs) at all of the researchers’ institutions recognize that the analysis of de-identified, publicly available data does not constitute human subjects research as defined in federal regulations and as such does not require IRB review. Hence, human subjects’ approval was not necessary since this was a de-identified data only study.

Results

An estimated 9,325,603 US adults with a diagnosis of NMCP were seen in primary care clinics in 2010 in the US. Table 2 displays data describing the study population --- US adults with NMCP. The data are displayed by the independent covariates and the dependent variable (opioid prescription) and are those used to perform the complex samples logistic regression analysis. Missing data were removed from the analysis as displayed in Table 2.
Table 2

Description of the study population (adults with NMCP) for SPSS complex samples logistic regression analysis

Variables and Factors

Weighted N*

Weighted %

Patient sex

Female

6868340

73.7

Male

2457263

26.3

Patient age

18-39

565172

6.1

40-64

4070522

43.6

> = 65

4689909

50.3

Race/Ethnicity

Caucasian

7406401

79.4

Non-Caucasian

1919202

20.6

Education percent of university graduates in patient zip code

<20%

5001646

53.6

> = 20%

4323957

46.4

Poverty percent in patient zip code

<10%

4988235

53.5

> = 10%

4337368

46.5

Health Insurance status

Have Health Insurance

8805283

94.4

Do Not Have Health Insurance

520320

5.6

Primary HCP visit

Yes

6195674

66.4

No

3129929

33.6

Patient now has arthritis

No

5087784

54.6

Yes

4237819

45.4

Patient now has depression

No

7726881

82.9

Yes

1598722

17.1

Geographic locale of patient

Rural

1966383

21.1

Non-Rural

7359220

78.9

Opioid prescription**

Other Medications

5928705

63.6

Opioids

3396898

36.4

*This weighted n is derived from a sample size of 2745, of which 2272 (82.8%) were non-rural residents and 473 (17.2%) rural residents.

**Study Dependent Variable.

NAMCS 2010 Data (weighted n =9,325,603).

The majority of the population 94.4% had health insurance and 66.4% were reported as having seen their primary HCP. Over seventy percent (73.7%) of the study population were women and 79.4% were Caucasian. In terms of the dependent variable 36.4% of the adult population with NMCP had an opioid prescription.

Bivariate analysis performed indicated that all of the study’s independent variables or covariates were significantly associated with the dependent variable (Table 3). Most importantly this bivariate analysis revealed that rural adults with NMCP had higher odds (OR =1.515, 95% CI =1.513 - 1.518) than similar non-rural adults of having a prescription for opioids.
Table 3

Bivariate analysis of US adults with a diagnosis of chronic pain and an opioid prescription as dependent variable by covariates

Variable

Factor

Unadjusted odds ratio (95% CI)

Patient sex (vs. Male)

Female

1.107 (1.104, 1.109)

Patient Race/Ethnicity (vs. Non-Caucasian)

Caucasian

.643 (.642, .644)

Education percent university graduate in patient zip code (vs. > = 20% )

<20%

1.010 (1.008, 1.012)

Poverty percent in patient zip code (vs. > = 10%)

<10%

1.036 (1.034, 1.037)

Health Insurance status (vs. Do Not Have Health Insurance)

Have Health Insurance

1.010 (1.006, 1.014)

Primary HCP visit (vs. No)

Yes

1.192 (1.190, 1.194)

Patient now has arthritis (vs. Yes)

No

.885 (.883, .886)

Patient now has depression (vs. Yes)

No

1.299 (1.295, 1.302)

Geographic local (vs. Non-Rural)

Rural

1.515 (1.513, 1.518)

Variable

Factors

%

Significance

Patient age range

18-39

6.1

< .001

40-64

43.6

> = 65

50.3

2010 NAMCS (weighted n =9,325,603).

Complex samples logistic regression was performed and the results are displayed in Table 4. Based on the bivariate analysis all of the study covariates were entered into the complex samples logistic regression model. Analysis yielded that two covariates were significantly associated with the dependent variable---rural residency (AOR =2.935, 95% CI 1.416-6.083) and non-Caucasian race/ethnicity (AOR =2.459, 95% CI 1.194-5.066).
Table 4

SPSS complex samples logistic regression analysis of US adults with NMCP (study dependent variable = opioid prescription)

Variables

Factors

Adjusted odds ratio (95% CI)

Patient sex

Female

1.310 (.631, 2.720)

Male

--*

Patient age

18-39

1.094 (.297, 4.027)

40-64

1.949 (.977, 3.887)

> = 65

--*

Race/Ethnicity

Caucasian

--*

Non-Caucasian

2.459 (1.194, 5.066)

Education percent of university graduates in patient zip code

<20%

--*

> = 20%

1.031 (.489, 2.175)

Poverty percent in patient zip code

<10%

1.713 (.876, 3.351)

> = 10%

--*

Primary HCP visit

Yes

1.162 (.515, 2.621)

No

--*

Health Insurance status

Have Health Insurance

1.371 (.584, 3.221)

Do Not Have Health Insurance

--*

Patient now has arthritis

Yes

1.309 (.514, 3.333)

No

--*

Patient now has depression

Yes

.518 (.246, 1.089)

No

--*

Geographic locale

Rural

2.935 (1.416, 6.083)

Non-Rural

--*

*Reference category.

NAMCS 2010 data (weighted n =9,325,603).

Discussion

Recently there has been much concern expressed about the over-prescribing of opioids [7],[28]-[30]. This concern arises from the fact that opioids are potentially addictive which can lead to misuse. Opioids have been cited as contributing to unnecessary morbidity and mortality, and in the long-run contribute to potentially unnecessary medical costs [4],[28]. We were interested in examining differences in rural and non-rural opioid prescribing patterns for NMCP management, hypothesizing that disparities exist in opioid prescribing patterns for rural populations in the US. Our analyses supported our hypothesis that rural residency is an independent risk factor for a greater probability of patients with NMCP being prescribed an opioid.

This research yielded important findings. First, rural residents had higher odds of having an opioid prescription than similar non-rural adults. Rural residency was the strongest predictor for having an opioid prescription and a diagnosis for NMCP. Second, being non-Caucasian was a strong predictor of having an opioid prescription and a diagnosis for NMCP.

Our results clearly indicate that rurality is an important factor in opioid prescribing patterns that cannot be ignored and bears further investigation. This is in stark difference to the finding of an earlier paper [24] that found no relationship between opioid prescription and geographic locale. At first glance one might conclude that this finding indicates an opioid prescribing disparity, but that may be too simple an explanation. All differences are not disparities. Disparities arise when the differences are avoidable as well as unjust [3],[18]. We cannot say with any certainty that these are the characteristics of the differences revealed in prescribing patterns from our analyses. It may be that there are treatment option limitations in rural areas of the US [31]. Ultimately, NMCP is complex and often requires a multifactorial approach for optimal management [32]. For instance, physical therapy, occupational therapy, massage therapy, acupuncture, integrated specialty pain management services, or behavioral modification may be useful approaches for the management of patients with NMCP [33]. These modalities as treatment options may be less available to patients in the rural US [31].

Our findings also identified that non-Caucasian race/ethnicity (African American, Hispanic, Asian, Native American, and multiracial) was an independent risk factor for having NMCP and being prescribed an opioid. Opioid prescribing patterns for non-Caucasian adults is complicated and the differences between our findings and those from a number of other studies are hard to reconcile or explain. Findings from multiple studies have yielded that African American or Black patients were less likely than Caucasian ones to be prescribed opioids for pain [12],[15],[16],[19],[34]-[37]. Other research has revealed that in the US there is little difference in the estimated prevalence of pain across population groups [38]. However, racial/ethnic minorities have often had inadequate pain management despite being more likely to report experiencing severe pain and/or pain that interfered with daily activities [3],[38]. One explanation for the variance of our findings from other studies might be the examination of data from a different source. The NAMCS data analyzed in this study is derived from patient health records rather than patient self-report surveys. Patient health record data are based on documented visits to health care providers, while patient self-report data are not. We do not want to make a claim of the veracity of one source of data over the other, only that the analysis of each may yield different findings.

Study limitations and strengths

This study does have some limitations, most of which are attributable to how the survey data were collected. First, ICD-9 codes were used to identify patients with NMCP and to limit the population included in the study. Second, opioid prescriptions were then assumed to be linked to the NMCP patient population. Since there is no link in the questionnaire form between prescribed medications (in our case opioids) and diagnosis (ICD-9 codes), we were unable to determine with surety for what diagnosis opioids were being prescribed for. However, this limitation is also present in a previously published study [4], setting precedence for using this methodology. Studies that can determine causality amongst these variables are warranted. Third, the variables of race/ethnicity, education, and household income were derived variables.

Nevertheless, this study has a number of strengths. Since we used national patient record population-level survey data, we had a large data set that was weighted to ensure that our findings could be more easily and accurately generalized to the US population. Another strength is the magnitude of the effect sizes for rural and non-rural opioid prescribing patterns as well as those detected for race/ethnicity. The effect sizes, derived from the logistic regression odds ratios, ranged from nearly two to three times greater than the reference categories. Much has been studied in reference to age and race/ethnicity, but these findings lend vigorous support to the conceptualization of rurality as a social determinant of health.

Conclusions

This study fills an important epidemiological knowledge gap regarding opioid prescribing patterns for rural adults with NMCP. Further research on the growing concern about the over-prescribing of opioids in the US should now include rurality as a variable in data generation and analysis in addition to the variable of race/ethnicity that are commonly included. In order to provide the best level of care to all patients regardless of geographic location or race/ethnicity, another level of analysis should capture data on opioid dosing and health care provider perceptions of patients. Future research should also attempt to document the ecological, sociological and political factors impacting opioid prescribing and care in rural communities. Prescribers and health care policy makers need to critically evaluate the implications of our findings and their relationship to patient needs, best practices in a rural setting, and the overall consequences of increased opioid prescribing on rural communities.

Authors’ contributions

JPP, KDH, AML, MTS, CAStH, GWA and MNL all made substantial contributions to the conception and design of the manuscript, contributed to the interpretation of the data, were involved in revising the manuscript critically for important intellectual content, and have given final approval of this version of the manuscript to be published. Additionally, MNL oversaw the statistical analyses and the acquisition of the data.

Authors’ information

Jacob P Prunuske, Catherine A St. Hill, Keri D Hager, Andrine M Lemieux, Michael T. Swanoski, Grant W Anderson and May N Lutfiyya as members of the Interprofessional Faculty Research Fellowship Program in the College of the Pharmacy at the University of Minnesota contributed equally to this project.

Abbreviations

AOR: 

Adjusted odds ratios

CDC: 

Centers for disease control and prevention

HCP: 

Health care provider

IRB: 

Institutional Review Board

MSA: 

Metropolitan Statistical Area

NAMCS: 

National Ambulatory Medical Care Survey

NCHS: 

National Center for Health Statistics

NMCP: 

Non-Malignant Chronic Pain

OR: 

Odds ratios

SPSS: 

Statistical Package for Social Scientists

Declarations

Disclosure

This research was supported by the College of Pharmacy at the University of Minnesota and the National Center for Interprofessional Education and Practice at the University of Minnesota.

Authors’ Affiliations

(1)
Department of Family Medicine and Community Health, School of Medicine, University of Minnesota
(2)
Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota
(3)
Department of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, University of Minnesota
(4)
Behavioral Medicine Laboratory, School of Medicine, University of Minnesota
(5)
National Center for Interprofessional Education and Practice, University of Minnesota, R685 Children’s Rehab Center

References

  1. Dubois MY, Gallagher RM, Lippe PM: Pain medicine position paper. Pain Med. 2009, 10: 972-1000. 10.1111/j.1526-4637.2009.00696.x.View ArticlePubMedGoogle Scholar
  2. International Association for the Study of Pain (IASP). Pain 1979, 6:250.Google Scholar
  3. Mossey JM: Defining racial and ethnic disparities in pain management. Clin Orthop Relat Res. 2011, 469: 1859-1870. 10.1007/s11999-011-1770-9.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Rasu RS, Sohraby R, Cunningham L, Knell ME: Assessing chronic pain treatment practices and evaluating adherence to chronic pain clinical guidelines in outpatient practices in the United States. J Pain. 2013, 6: 568-578. 10.1016/j.jpain.2013.01.425.View ArticleGoogle Scholar
  5. American Academy of Pain Medicine: AAPM Facts and Figures on Pain. Available at: . Accessed 13 November 2013, [http://www.painmed.org/patient/facts.html]
  6. Committee on Advancing Pain Research, Care, and Education; Institute of Medicine: Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education and Research. Available at: . Accessed 13 November 2013, [http://www.nap.edu/catalog.php?record_id=131722]
  7. Okie S: A flood of opioids, a rising tide of deaths. N Engl J Med. 2010, 363: 1981-1984. 10.1056/NEJMp1011512.View ArticlePubMedGoogle Scholar
  8. Hardt J, Jacobsen C, Goldberg J, Nickel R, Buchwald D: Prevalence of chronic pain in a representative sample in the United States. Pain Med. 2008, 9: 803-812. 10.1111/j.1526-4637.2008.00425.x.View ArticlePubMedGoogle Scholar
  9. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R: Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003, 290: 2443-2454. 10.1001/jama.290.18.2443.View ArticlePubMedGoogle Scholar
  10. Califano JA: Under the counter: The diversion and abuse of controlled prescription drugs in the US. The National Center on Addiction and Substance Abuse; Columbia University: 2005Google Scholar
  11. Meltzer EC, Rybin D, Saitz R, Samet JH, Schwartz SL, Butler SF, Liebschutz JM: Identifying prescription opioid use disorder in primary care: Diagnostic characteristics of the Current Opioid Misuse Measure (COMM). Pain. 2011, 152: 397-402. 10.1016/j.pain.2010.11.006.View ArticlePubMedGoogle Scholar
  12. Heins JK, Heins A, Grammas M, Costello M, Huang K, Mishra S: Disparities in analgesia and opioid prescribing practices for patients with musculoskeletal pain in the emergency department. J Emerg Nurs. 2006, 32: 219-224. 10.1016/j.jen.2006.01.010.View ArticlePubMedGoogle Scholar
  13. Marcus D: Gender and ethnic differences in pain. Experience Chronic Pain: A Primary Care Guide to Practical Management. Humana Press (a part of Springer Science + Business Media, LLC). 2009Google Scholar
  14. Crowley-Matoka M: How to parse the protective, the punitive and the prejudicial in chronic opioid therapy. Pain. 2013, 154: 5-6. 10.1016/j.pain.2012.10.013.View ArticlePubMedGoogle Scholar
  15. Hausmann LRM, Gao S, Lee ES, Kwoh CK: Racial disparities in the monitoring of patients on chronic opioid therapy. Pain. 2013, 154: 46-52. 10.1016/j.pain.2012.07.034.View ArticlePubMedGoogle Scholar
  16. Shavers VL, Bakos A, Sheppard VB: Race, ethnicity and pain among the U.S. adult population. J Health Care Poor Underserved. 2010, 21: 177-220. 10.1353/hpu.0.0255.View ArticlePubMedGoogle Scholar
  17. Coffey RM, Andrews RM, Moy E: Racial, ethnic, and socioeconomic disparities in estimates of AHRQ patient safety indicators. Med Care. 2005, 43: s148-s157. 10.1097/00005650-200503001-00008.View ArticleGoogle Scholar
  18. Lutfiyya MN, McCullough JE, Haller IV, Waring SC, Bianco JA, Lipsky MS: Rurality as a root or fundamental social determinant of health. Disease a Month. 2012, 58: 620-628. 10.1016/j.disamonth.2012.08.005.View ArticlePubMedGoogle Scholar
  19. Pletcher MJ, Kertesz SG, Kohn MA, Gonzales R: Trends in opioid prescribing by race/ethnicity for patients seeking care in US emergency departments. JAMA. 2008, 299: 70-78.PubMedGoogle Scholar
  20. Curtis LH, Stoddard J, Radeva JI, Hutchison S, Dans PE, Wright A, Woosley RL, Schulman KA: Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States. Health Serv Res. 2006, 41: 856-858. 10.1111/j.1475-6773.2006.00573.x.View ArticlePubMed CentralGoogle Scholar
  21. McDonald DC, Carlson K, Izrael D: Geographic variation in opioid prescribing in the U.S. J Pain. 2012, 13: 988-996. 10.1016/j.jpain.2012.07.007.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Zerzan JT, Morden NE, Soumerai S, Ross-Degnan D, Roughead E, Zhang F, Simoni-Wastila L, Sullivan SD: Trends and geographic variation of opiate medication use in state Medicaid fee-for-service programs, 1996 to 2002. Med Care. 2006, 44: 1005-1010. 10.1097/01.mlr.0000228025.04535.25.View ArticlePubMedGoogle Scholar
  23. Kelly JP, Cook SF, Kaufman DW, Anderson T, Rosenberg L, Mitchell AA: Prevalence and characteristics of opioid use in the US adult population. Pain. 2008, 138: 507-513. 10.1016/j.pain.2008.01.027.View ArticleGoogle Scholar
  24. Olsen Y, Daumit GL, Ford DE: Opioid prescriptions by U.S. primary care physicians from 1992 to 2001. J Pain. 2006, 7: 225-235. 10.1016/j.jpain.2005.11.006.View ArticlePubMedGoogle Scholar
  25. National Ambulatory Medical Care Survey. 2013Google Scholar
  26. Grattan A, Sullivan MD, Saunders KW, Campbell CI, Von Korf MR: Depression and prescription opioid misuse among chronic opioid therapy recipients with no history of substance abuse. Ann Fam Med. 2012, 10: 304-311. 10.1370/afm.1371.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Stein C, Baerwald C: Opioids for the treatment of arthritis pain. Expert Opin Pharmacother. 2014, 15: 193-202. 10.1517/14656566.2014.861818.View ArticlePubMedGoogle Scholar
  28. Chou R, Ballantyne JC, Fanciullo GJ, Fine PG, Miaskowski C: Research gaps on use of opioids for chronic non cancer pain: findings from a review of the evidence for an American pain society and American academy of pain medicine clinical practice guideline. J Pain. 2009, 10: 147-159. 10.1016/j.jpain.2008.10.007.View ArticlePubMedGoogle Scholar
  29. Pizzo PA, Clark NM: Alleviating suffering 101 - pain relief in the United States. N Engl J Med. 2012, 366: 197-199. 10.1056/NEJMp1109084.View ArticlePubMedGoogle Scholar
  30. Sehgal N, Manchikanti L, Smith HS: Prescription Opioid Abuse in Chronic Pain: A Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse. Pain Physician. 2012, 15: ES67-ES92.PubMedGoogle Scholar
  31. Hoffman PK BS, Meier BP MS, Council JR: A comparison of chronic pain between an urban and rural population. J Community Health Nurs. 2002, 19: 213-224. 10.1207/S15327655JCHN1904_02.View ArticlePubMedGoogle Scholar
  32. Reid MC, Engles-Horton LL, Weber MB, Kerns RD, Rogers EL, O’Connor PG: Use of opioid medications for chronic non cancer pain syndromes in primary care. J Gen Intern Med. 2002, 17: 173-179. 10.1046/j.1525-1497.2002.10435.x.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Breivik H: Opioids in chronic non-cancer pain, indications and controversies. Eur J Pain. 2000, 9: 127-130. 10.1016/j.ejpain.2004.05.013.View ArticleGoogle Scholar
  34. Chen I, Kurz J, Pasanen M, Faselis C, Panda M, Staton LJ, O’Rorke J, Menon M, Genao I, Wood J, Mechaber AJ, Rosenberg E, Carey T, Calleson D, Cykert S: Racial differences in opioid use for chronic nonmalignant pain. J Gen Intern Med. 2005, 20: 593-598. 10.1007/s11606-005-0105-5.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Tamayo-Sarver JH, Dawson NV, Hinze SW, Cydulka RK, Wigton RS, Albert JM, Ibrahim SA, Baker DW: The effect of race/ethnicity and desirable social characteristics on physicians’ decisions to prescribe opioid analgesics. Acad Emerg Med. 2003, 10: 1239-1248. 10.1111/j.1553-2712.2003.tb00608.x.View ArticlePubMedGoogle Scholar
  36. Tamayo-Sarver JH, Hinze SW, Cydulka RK, Baker DW: Racial and ethnic disparities in emergency department analgesic prescription. Am J Public Health. 2003, 93: 2067-73. 10.2105/AJPH.93.12.2067.View ArticlePubMedPubMed CentralGoogle Scholar
  37. Terrell KM, Hui SL, Castelluccio P, Kroenke K, McGrath RB, Miller DK: Analgesic prescribing for patients who are discharged from an emergency department. Pain Med. 2010, 11: 1072-7. 10.1111/j.1526-4637.2010.00884.x.View ArticlePubMedGoogle Scholar
  38. Stinson FS, Grant BF, Dawson DA, Ruan WJ, Huang B, Saha T: Comorbidity between DSM-IV alcohol and specific drug use disorders in the United States: results from the National Epidemiologic Survey of Alcohol and Related Conditions. Drug Alcohol Depend. 2005, 80: 105-116. 10.1016/j.drugalcdep.2005.03.009.View ArticlePubMedGoogle Scholar

Copyright

© Prunuske et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.